Vanguard Group
IMDX

Vanguard Group’s Insight Molecular Diagnostics IMDX Stock Holding History

Vanguard Group’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$3.95M Buy
526,675
+39,937
+8% +$225K ﹤0.01% 3345
2025
Q3 		$1.62M Buy
486,738
+2,967
+0.6% +$8.37K ﹤0.01% 3643
2025
Q2 		$1.46M Buy
483,771
+218,314
+82% +$660K ﹤0.01% 3639
2025
Q1 		$812K Buy
265,457
+23,251
+10% +$62.9K ﹤0.01% 3773
2024
Q4 		$576K Sell
242,206
-3,182
-1% -$8.65K ﹤0.01% 3909
2024
Q3 		$699K Buy
245,388
+899
+0.4% +$2.79K ﹤0.01% 3884
2024
Q2 		$721K Sell
244,489
-3,384
-1% -$9.3K ﹤0.01% 3895
2024
Q1 		$726K Hold
247,873
– – ﹤0.01% 3907
2023
Q4 		$620K Buy
247,873
+7,784
+3% +$24K ﹤0.01% 3972
2023
Q3 		$749K Buy
240,089
+22,129
+10% +$82.3K ﹤0.01% 3934
2023
Q2 		$1M Hold
217,960
– – ﹤0.01% 3897
2023
Q1 		$1.54M Hold
217,960
– – ﹤0.01% 3773
2022
Q4 		$1.4M Buy
217,960
+125
+0.1% +$1.38K ﹤0.01% 3794
2022
Q3 		$3.18M Buy
217,835
+508
+0.2% +$8.79K ﹤0.01% 3552
2022
Q2 		$3.91M Buy
217,327
+18,013
+9% +$410K ﹤0.01% 3508
2022
Q1 		$5.94M Buy
199,314
+4,527
+2% +$145K ﹤0.01% 3448
2021
Q4 		$8.45M Buy
194,787
+988
+0.5% +$56.8K ﹤0.01% 3313
2021
Q3 		$13.8M Sell
193,799
-1,653
-0.8% -$152K ﹤0.01% 3065
2021
Q2 		$22.4M Buy
195,452
+7,639
+4% +$746K ﹤0.01% 2780
2021
Q1 		$19.5M Buy
187,813
+52,527
+39% +$4.99M ﹤0.01% 2797
2020
Q4 		$6.47M Buy
135,286
+39,272
+41% +$1.44M ﹤0.01% 3220
2020
Q3 		$2.67M Buy
96,014
+5,339
+6% +$153K ﹤0.01% 3401
2020
Q2 		$3.46M Buy
90,675
+19,572
+28% +$1.01M ﹤0.01% 3254
2020
Q1 		$3.48M Buy
71,103
+6,033
+9% +$296K ﹤0.01% 3124
2019
Q4 		$2.93M Sell
65,070
-170
-0.3% -$6.13K ﹤0.01% 3340
2019
Q3 		$2.74M Sell
65,240
-5,456
-8% -$214K ﹤0.01% 3344
2019
Q2 		$3.52M Buy
70,696
+7,825
+12% +$651K ﹤0.01% 3292
2019
Q1 		$4.97M Buy
62,871
+45,835
+269% +$2.96M ﹤0.01% 3148
2018
Q4 		$470K Sell
17,036
-3,478
-17% -$125K ﹤0.01% 3749
2018
Q3 		$1.03M Buy
20,514
+756
+4% +$39K ﹤0.01% 3712
2018
Q2 		$1.01M Buy
19,758
+1,981
+11% +$97.6K ﹤0.01% 3687
2018
Q1 		$747K Sell
17,777
-67
-0.4% -$4.43K ﹤0.01% 3714
2017
Q4 		$1.66M Buy
17,844
+11,157
+167% +$1.26M ﹤0.01% 3479
2017
Q3 		$1.01M Buy
6,687
+1,253
+23% +$131K ﹤0.01% 3589
2017
Q2 		$565K Buy
5,434
+545
+11% +$62K ﹤0.01% 3704
2017
Q1 		$584K Buy
4,889
+45
+0.9% +$5.2K ﹤0.01% 3724
2016
Q4 		$683K Buy
4,844
+250
+5% +$27.5K ﹤0.01% 3663
2016
Q3 		$463K Buy
4,594
+145
+3% +$11.7K ﹤0.01% 3772
2016
Q2 		$317K Sell
4,449
-307
-6% -$28.7K ﹤0.01% 3872
2016
Q1 		$439K Buy
+4,756
New +$421K ﹤0.01% 3817

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group's IMDX Position: Q4 2025 in Review

Vanguard Group increased its Insight Molecular Diagnostics (IMDX) stake by 8.2% in Q4 2025, buying an estimated $225K and bringing the position to 526,675 shares worth $3.95M. The position accounts for ﹤0.01% of the portfolio, ranked #3345.

Vanguard Group first reported a position in IMDX in Q1 2016 and has held it in 40 quarters since. The position peaked at $22.4M in Q2 2021. 35 funds tracked by Wall St. Rank hold IMDX as of Q4 2025.

  • Vanguard Group held 526,675 shares of Insight Molecular Diagnostics worth $3.95M as of Q4 2025.
  • Vanguard Group bought 39,937 Insight Molecular Diagnostics shares in Q4 2025, an estimated $225K.
  • Insight Molecular Diagnostics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3345 holding.
  • Vanguard Group first reported a position in Insight Molecular Diagnostics in Q1 2016 and has held it in 40 quarters since.
  • Vanguard Group's Insight Molecular Diagnostics position peaked at $22.4M in Q2 2021.
  • 35 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.